Abstract
Breast cancer is the most common cancer amongst women in the United States and around the world. Although widespread use of adjuvant chemotherapeutic and hormonal agents has improved mortality from breast cancer, it remains challenging to determine on an individual basis who will benefit from such treatments and who will be likely to encounter toxicities. With the rising costs of healthcare and the introduction of new targeted therapies, use of biomarkers has emerged as a method of assisting with breast cancer diagnosis, prognosis, prediction of therapeutic response, and surveillance of disease during and after treatment. In the following review, prognostic and therapeutic biomarkers, their utility in the management of patients with breast cancer, and current recommendations regarding their clinical use will be discussed.
Keywords: Breast cancer, biomarker, diagnosis, prognosis, treatment, recurrence, metastasis, carditoxicity.
Current Pharmaceutical Design
Title:Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence
Volume: 20 Issue: 30
Author(s): Amy M. Braden, Rachel V. Stankowski, Jessica M. Engel and Adedayo A. Onitilo
Affiliation:
Keywords: Breast cancer, biomarker, diagnosis, prognosis, treatment, recurrence, metastasis, carditoxicity.
Abstract: Breast cancer is the most common cancer amongst women in the United States and around the world. Although widespread use of adjuvant chemotherapeutic and hormonal agents has improved mortality from breast cancer, it remains challenging to determine on an individual basis who will benefit from such treatments and who will be likely to encounter toxicities. With the rising costs of healthcare and the introduction of new targeted therapies, use of biomarkers has emerged as a method of assisting with breast cancer diagnosis, prognosis, prediction of therapeutic response, and surveillance of disease during and after treatment. In the following review, prognostic and therapeutic biomarkers, their utility in the management of patients with breast cancer, and current recommendations regarding their clinical use will be discussed.
Export Options
About this article
Cite this article as:
Braden M. Amy, Stankowski V. Rachel, Engel M. Jessica and Onitilo A. Adedayo, Breast Cancer Biomarkers: Risk Assessment, Diagnosis, Prognosis, Prediction of Treatment Efficacy and Toxicity, and Recurrence, Current Pharmaceutical Design 2014; 20 (30) . https://dx.doi.org/10.2174/1381612819666131125145517
DOI https://dx.doi.org/10.2174/1381612819666131125145517 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Autophagic Pathways by Plant Natural Compounds in Cancer Treatment
Current Drug Targets The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry In vivo Real-Time Near-Infrared Fluorescent Mapping of Sentinel Lymph Nodes Using Methylene Blue Encapsulated in a Microemulsion Nanosystem
Current Nanoscience Transmission Electron Microscopy as Key Technique for the Characterization of Telocytes
Current Stem Cell Research & Therapy Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry The Role of TNFSF15 in the Modulation of Neovascularization and Inflammation
Current Hypertension Reviews Alpha-1-Antichymotrypsin: A Common Player for Type 2 Diabetes and Alzheimer's Disease
Current Diabetes Reviews Status Epilepticus: An Overview
Current Drug Metabolism Significant Metabolites and Outlier-Robust Classifier Identification for Breast Cancer Prediction
Current Metabolomics Model Checking a Synchronous Diabetes-Cancer Logical Network
Current Bioinformatics Snake Venom Phospholipases A2: A New Class of Antitumor Agents
Protein & Peptide Letters Can we Target the Chemokine Network for Cancer Therapeutics?
Current Cancer Drug Targets Combined Therapies of Bone Disease with Bisphosphonates
Current Pharmaceutical Design An Orally Bioavailable c-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth
Anti-Cancer Agents in Medicinal Chemistry Quassinoids: From Traditional Drugs to New Cancer Therapeutics
Current Medicinal Chemistry Targeted Therapy Towards Cancer-A Perspective
Anti-Cancer Agents in Medicinal Chemistry Drug Targeting Based on a New Concept-Targeting Against TLR4 as an Example
Endocrine, Metabolic & Immune Disorders - Drug Targets NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets MicroRNAs and Cancer: Towards a Personalized Medicine
Current Molecular Medicine Computational Studies in Drug Design Against Cancer
Anti-Cancer Agents in Medicinal Chemistry